Market Challenges And Opportunities

Global Peptide Cancer Vaccine Market Dynamics

Increasing prevalence of cancer and failure of conventional methods for the treatment of the disease effectively has led to increasing demand for new immunotherapy-based therapies such as peptide vaccine. According to a National Cancer Institute, 2016, in the U.S., it was estimated that 16.8 million new cases of cancer were diagnosed with an approximate 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024. Furthermore, the World Health Organization (WHO) reported around 14 million cases of cancer and 8.2 million deaths caused by the disease in 2012. Among these, the common cases pertained to lung, colorectal, prostate, cervical, and breast cancer, which significantly has increased demand for peptide vaccines, in turn aiding in growth of the global peptide cancer vaccine market.

Restraints

In the recent past, results of clinical trials performed using peptide cancer vaccine had exhibited negative outcomes. So, researchers in the peptide vaccine have considered this as outdated therapy and declared it as no longer viable for cancer treatment. However, increasing progress in understanding critical role of immune adjuvants, modes of vaccine administration, and T cell dynamics has led to re-emergence of this approach for the treatment of malignant disorders.